Cargando…

Apremilast in Refractory Alopecia Areata

Alopecia areata (AA) is a common disease characterized by nonscarring hair loss. There are no satisfactory therapies for extensive cases. Systemic immune suppressants are usually used despite their nonspecific actions and often associated side effects. Apremilast is an oral, small-molecule, inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Estébanez, Andrea, Estébanez, Nuria, Martín, Jose M, Montesinos, Encarna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830030/
https://www.ncbi.nlm.nih.gov/pubmed/31728104
http://dx.doi.org/10.4103/ijt.ijt_59_19
_version_ 1783465696958611456
author Estébanez, Andrea
Estébanez, Nuria
Martín, Jose M
Montesinos, Encarna
author_facet Estébanez, Andrea
Estébanez, Nuria
Martín, Jose M
Montesinos, Encarna
author_sort Estébanez, Andrea
collection PubMed
description Alopecia areata (AA) is a common disease characterized by nonscarring hair loss. There are no satisfactory therapies for extensive cases. Systemic immune suppressants are usually used despite their nonspecific actions and often associated side effects. Apremilast is an oral, small-molecule, inhibitor of phosphodiesterase 4 approved for the treatment of psoriasis and psoriatic arthritis. Its use in AA has shown variable results. Whereas a recent reduced clinical trial concluded a lack of efficacity, several case reports demonstrate a significant improvement. We report four cases of extensive AA successfully treated with apremilast.
format Online
Article
Text
id pubmed-6830030
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-68300302019-11-14 Apremilast in Refractory Alopecia Areata Estébanez, Andrea Estébanez, Nuria Martín, Jose M Montesinos, Encarna Int J Trichology Case Report Alopecia areata (AA) is a common disease characterized by nonscarring hair loss. There are no satisfactory therapies for extensive cases. Systemic immune suppressants are usually used despite their nonspecific actions and often associated side effects. Apremilast is an oral, small-molecule, inhibitor of phosphodiesterase 4 approved for the treatment of psoriasis and psoriatic arthritis. Its use in AA has shown variable results. Whereas a recent reduced clinical trial concluded a lack of efficacity, several case reports demonstrate a significant improvement. We report four cases of extensive AA successfully treated with apremilast. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6830030/ /pubmed/31728104 http://dx.doi.org/10.4103/ijt.ijt_59_19 Text en Copyright: © 2019 International Journal of Trichology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Estébanez, Andrea
Estébanez, Nuria
Martín, Jose M
Montesinos, Encarna
Apremilast in Refractory Alopecia Areata
title Apremilast in Refractory Alopecia Areata
title_full Apremilast in Refractory Alopecia Areata
title_fullStr Apremilast in Refractory Alopecia Areata
title_full_unstemmed Apremilast in Refractory Alopecia Areata
title_short Apremilast in Refractory Alopecia Areata
title_sort apremilast in refractory alopecia areata
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830030/
https://www.ncbi.nlm.nih.gov/pubmed/31728104
http://dx.doi.org/10.4103/ijt.ijt_59_19
work_keys_str_mv AT estebanezandrea apremilastinrefractoryalopeciaareata
AT estebaneznuria apremilastinrefractoryalopeciaareata
AT martinjosem apremilastinrefractoryalopeciaareata
AT montesinosencarna apremilastinrefractoryalopeciaareata